FDA Inspection 1329592 — Dong Ki Kim, MD, PhD
The FDA completed an inspection of Dong Ki Kim, MD, PhD on Jul 31, 2026 in Seoul. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 31, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seoul (Korea (the Republic of))
Additional Details
Clinical Investigator (CI)